文献速递临床试验与 GCP流行病学与生物统计

经皮冠状动脉介入治疗后P2Y12抑制剂或阿司匹林:随机临床试验的个体患者数据Meta分析

P2Y12 inhibitor or aspirin after percutaneous coronary intervention: individual patient data meta-analysis of randomised clinical trials.
PubMed 文献 · BMJ · 2025-06-04

该个体患者数据Meta分析纳入5项随机试验共16117例PCI后完成推荐DAPT的患者,比较P2Y12抑制剂单药与阿司匹林单药。中位随访1351天,P2Y12抑制剂单药与MACCE风险降低相关(HR 0.77,95%CI 0.67-0.89,P<0.001),大出血无显著差异(HR 1.26,95%CI 0.78-2.04,P=0.35)。

要点

  • PCI后停用DAPT,P2Y12抑制剂单药较阿司匹林单药降低MACCE风险(HR 0.77,95%CI 0.67-0.89)。
  • P2Y12抑制剂单药未增加大出血风险(HR 1.26,95%CI 0.78-2.04,P=0.35)。
  • NACCE、心肌梗死和卒中在P2Y12抑制剂组均低于阿司匹林组。

核心结论

  • 在PCI后停用DAPT的患者中,随访约5.5年时,替格瑞洛或氯吡格雷单药治疗与MACCE降低相关,归因于心肌梗死和卒中发生率降低,且未伴随大出血风险增加。

研究设计与样本

  • 研究设计为随机临床试验的个体参与者数据Meta分析。
  • 数据来源为PubMed/Medline、Scopus、Web of Science和Ovid/Embase。
  • 纳入5项随机试验共16117例PCI后完成推荐DAPT方案(中位疗程12个月)并分配至P2Y12抑制剂或阿司匹林单药的患者。
  • 数据主要采用混合效应模型(一步法分析)合并,并辅以多变量混合效应模型和基于随机效应模型的二步法分析。
  • 主要结局为MACCE复合终点,共同主要结局为大出血。

主要发现

  • 中位随访1351天(四分位距373-1791天),P2Y12抑制剂单药较阿司匹林单药降低MACCE风险:一步法分析HR 0.77(95%CI 0.67-0.89),P<0.001;多变量一步法分析校正HR 0.77(95%CI 0.67-0.89),P<0.001;二步法分析HR 0.77(95%CI 0.67-0.89),P<0.001。
  • MACCE获益的需治疗人数为45.5(95%CI 31.4-93.6)。
  • 大出血无显著差异:一步法分析HR 1.26(95%CI 0.78-2.04),P=0.35;多变量一步法分析HR 1.12(95%CI 0.74-1.70),P=0.60;二步法分析HR 1.15(95%CI 0.69-1.92),P=0.59。
  • NACCE、心肌梗死和卒中在分配至P2Y12抑制剂的患者中低于分配至阿司匹林的患者。
  • 上述发现在多项敏感性和亚组分析中得到证实。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the long term comparative effectiveness of P2Y12 inhibitor monotherapy compared with aspirin monotherapy in patients after percutaneous coronary intervention (PCI) and discontinuation of dual antiplatelet therapy (DAPT). DESIGN: Individual participant data (IPD) meta-analysis of randomised clinical trials. DATA SOURCES: PubMed/Medline, Scopus, Web of Science, and Ovid/Embase. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Randomised trials investigating monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention of ischaemic events in patients with coronary artery disease who underwent PCI. DATA EXTRACTION AND SYNTHESIS: Anonymised IPD were extracted and transferred to the coordinating centre by dedicated electronic spreadsheets. Data were primarily combined by mixed effects models (one stage analysis) and complemented with multivariable mixed effects models and two stage analyses based on random effects models. The primary and co-primary outcomes were a composite of major adverse cardiac and cerebrovascular events (MACCE) and major bleeding, respectively. The secondary outcomes included a net composite of adverse cardiac and cerebrovascular events (NACCE), derived from the combination of the primary and co-primary outcomes, and individual ischaemic and bleeding events. RESULTS: A total of 16 117 patients assigned to P2Y12 inhibitor or aspirin monotherapy after PCI and completion of the recommended DAPT regimen (median duration of 12 months) in five randomised trials were included. At a median follow-up of 1351 days (interquartile range 373-1791 days), P2Y12 inhibitor monotherapy was associated with a lower risk of MACCE compared with aspirin monotherapy (one stage analysis: hazard ratio 0.77 (95% confidence interval (CI) 0.67 to 0.89), P<0.001; multivariable one stage analysis: adjusted hazard ratio 0.77 (0.67 to 0.89), P<0.001; two stage analysis: hazard ratio 0.77 (0.67 to 0.89), P<0.001), yielding a number needed to treat to benefit of 45.5 (95% CI 31.4 to 93.6). No significant difference in major bleeding (one stage analysis: hazard ratio 1.26 (0.78 to 2.04), P=0.35; multivariable one stage analysis: 1.12 (0.74 to 1.70), P=0.60; two stage analysis: 1.15 (0.69 to 1.92), P=0.59) was observed. NACCE, myocardial infarction, and stroke were lower in patients assigned to a P2Y12 inhibitor compared with those assigned to aspirin. These findings were confirmed across multiple sensitivity and subgroup analyses. CONCLUSIONS: In patients who had undergone PCI and discontinued DAPT, at a follow-up of about 5.5 years, P2Y12 inhibitor monotherapy with ticagrelor or clopidogrel was associated with lower MACCE, owing to reduced rates of myocardial infarction and stroke compared with aspirin monotherapy, without a concurrent increased risk of major bleeding. REVIEW REGISTRATION: PROSPERO CRD42024517983.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Giacoppo D, Gragnano F, Watanabe H, et al. P2Y12 inhibitor or aspirin after percutaneous coronary intervention: individual patient data meta-analysis of randomised clinical trials. BMJ. 2025. PMID: 40467090. doi:10.1136/bmj-2024-082561

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。